Self-management for Men With Uncomplicated Lower Urinary Tract Symptoms
1 other identifier
interventional
168
0 countries
N/A
Brief Summary
Objective To test the hypothesis that a nurse-led self-management programme is effective for men with uncomplicated lower urinary tract symptoms. This will be achieved by comparing symptom seveirty and the amount of drug therapy used to manage these symptoms in men who attend a self-management programme, compared to those who do not. Study design This study will use the format of a randomised controlled trial. 200 new patients with uncomplicated LUTS will be randomised to either attend or not attend (standard therapy) a self-management programme. The programme provides education, reassurance, prostate cancer risk, advice on lifestyle modifications (e.g. fluids - type and amount), concurrent medication re-scheduling and behavioural changes (double-voiding, strategies for dribbling, and bladder re-training). These strategies are learnt through group discussion, problem solving and goal setting. All men start the study with a period of watchful waiting (monitoring symptoms only) and are followed up for a total of 1 year. At each assessment (baseline, 3, 6, and 12 months) symptom severity and the use of drug therapy to control symptoms will be compared between the two groups. The only difference between them is that one group has attended a self-management programme and the other has not. Potential application of results Self-management focuses on patient involvement in health care by involving them in the day-to-day control of their symptoms. If effective, self-management may provide a long-term method of managing LUTS without using drug therapy, thereby offering considerable health gain and financial savings. The NHS Modernisation Agency wishes to develop the role of the nurse specialist to manage some patients independently of doctors. Nurse-led LUTS assessment clinics are now well established, perhaps nurses managing these patients with self-management interventions may become part of standard therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Jan 2004
Typical duration for phase_3
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2004
CompletedFirst Submitted
Initial submission to the registry
December 22, 2005
CompletedFirst Posted
Study publicly available on registry
December 26, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2006
CompletedMay 6, 2015
December 1, 2005
3 months
December 22, 2005
May 5, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
treatment failure (use of drug therapy for symptom control, surgical intervention, symptom deterioration of 3 points or more measured with the I-PSS, acute urinary retention, or death)
Secondary Outcomes (6)
quality of life / bother assessment (BPH Impact Index)
Short Form-36
Illness Perception Questionnaire - IPQ
health-seeking behaviour (unscheduled clinic, A&E or GP visits)
infection
- +1 more secondary outcomes
Interventions
Eligibility Criteria
You may qualify if:
- new patients with uncomplicated LUTS (I-PSS score 0-35)
- aged 40 years and over
- referred for the first time by their family doctor (general practitioner) to one of a participating urological outpatient departments
You may not qualify if:
- lower urinary tract symptoms due to any urological malignancy
- previous prostatic surgery within the last 10 years or pelvic radiotherapy
- complications of urinary obstruction (acute or chronic urinary retention - post micturition volumes over 300ml, bladder stones, renal failure, recurrent urinary tract infection or haematuria)
- uncontrolled diabetes, dementia and end stage cardiac or respiratory failure
- inability to speak or understand the English language
- severe symptoms where drug therapy or surgical management is indicated or requested by the patient
- medical therapy for lower urinary tract symptoms in the previous 3 months, including alpha-blockers, 5-alpha reductase inhibitors (finasteride) or anti-cholinergics.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (4)
Brown CT, van der Meulen J, Mundy AR, O'Flynn E, Emberton M. Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. Eur Urol. 2004 Aug;46(2):254-62; discussion 263. doi: 10.1016/j.eururo.2004.02.008.
PMID: 15245822BACKGROUNDBrown CT, Van Der Meulen J, Mundy AR, Emberton M. Lifestyle and behavioural interventions for men on watchful waiting with uncomplicated lower urinary tract symptoms: a national multidisciplinary survey. BJU Int. 2003 Jul;92(1):53-7. doi: 10.1046/j.1464-410x.2003.04268.x.
PMID: 12823383BACKGROUNDNewman S, Steed L, Mulligan K. Self-management interventions for chronic illness. Lancet. 2004 Oct 23-29;364(9444):1523-37. doi: 10.1016/S0140-6736(04)17277-2.
PMID: 15500899BACKGROUNDBrown CT, Yap T, Cromwell DA, Rixon L, Steed L, Mulligan K, Mundy A, Newman SP, van der Meulen J, Emberton M. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ. 2007 Jan 6;334(7583):25. doi: 10.1136/bmj.39010.551319.AE. Epub 2006 Nov 21.
PMID: 17118949DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christian Brown
Clinical Effectiveness Unit, The Royal College of Surgeons of England
- STUDY CHAIR
Mark Emberton
Clinical Effectiveness Unit, The Royal College of Surgeons of England
- STUDY DIRECTOR
Jan HP Van der Meulen, PhD
Clinical Effectiveness Unit, The Royal College of Surgeons of England
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 22, 2005
First Posted
December 26, 2005
Study Start
January 1, 2004
Primary Completion
April 1, 2004
Study Completion
October 1, 2006
Last Updated
May 6, 2015
Record last verified: 2005-12